Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Bresler AG, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P. Adès L, et al. Among authors: sebert m. Haematologica. 2012 Feb;97(2):213-8. doi: 10.3324/haematol.2011.045914. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993675 Free PMC article.
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases.
Zakine È, Papageorgiou L, Bourguiba R, Mekinian A, Terrier B, Kosmider O, Hirsch P, Jachiet M, Audia S, Ardois S, Adélaïde L, Bigot A, Duriez P, Emile JF, Lazaro E, Fayard D, Galland J, Hié M, Humbert S, Jean A, Kostine M, Lacombe V, Le Guenno G, Lobbes H, Magy-Bertrand N, Marianetti-Guingel P, Mathian A, Outh R, Saillard C, Samson M, Vial G, Bouaziz JD, Moguelet P, Chasset F; National French VEXAS Study Group (NFVS). Zakine È, et al. J Am Acad Dermatol. 2023 Apr;88(4):917-920. doi: 10.1016/j.jaad.2022.10.052. Epub 2022 Nov 5. J Am Acad Dermatol. 2023. PMID: 36343774 No abstract available.
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S. Thépot S, et al. Among authors: sebert m. Cell Cycle. 2011 Jul 15;10(14):2323-30. doi: 10.4161/cc.10.14.16399. Epub 2011 Jul 15. Cell Cycle. 2011. PMID: 21654193
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L. Le Bras F, et al. Among authors: sebert m. Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28. Leuk Res. 2011. PMID: 21715006
Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML.
Sébert M, Porcher R, Robin M, Adès L, Boissel N, Raffoux E, Xhaard A, Dhedin N, Larghero J, Himberlin C, Delmer A, Fenaux P, Dombret H, Socié G, de Latour RP. Sébert M, et al. Bone Marrow Transplant. 2015 Jan;50(1):74-81. doi: 10.1038/bmt.2014.199. Epub 2014 Sep 22. Bone Marrow Transplant. 2015. PMID: 25243624 Clinical Trial.
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Thepot S, et al. Among authors: sebert m. Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7. Leuk Res. 2014. PMID: 25449687 Clinical Trial.
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, Micol JB, Esterni B, Itzykson R, Thepot S, Recher C, Delaunay J, Dreyfus F, Mufti G, Fenaux P, Vey N. Wanquet A, et al. Among authors: sebert m. Am J Hematol. 2015 Oct;90(10):859-63. doi: 10.1002/ajh.24099. Epub 2015 Jul 14. Am J Hematol. 2015. PMID: 26113240 Free article.
102 results